News | Clinical Decision Support | July 15, 2016

NCCN Accepted as CMS-Approved Provider-Led Entity for Development of Imaging Appropriate Use Criteria

NCCN joins 10 other multidisciplinary organizations as a qualified provider-led entity under the Medicare Appropriate Use Criteria (AUC) program for advanced diagnostic imaging

The National Comprehensive Cancer Network (NCCN), an alliance of 27 of the nation’s leading cancer centers, has been recognized as a qualified provider-led entity (PLE) for the new Medicare Appropriate Use Criteria (AUC) Program by Centers for Medicare & Medicaid Services (CMS). Through this qualification, CMS — the nation’s largest health payer — recognizes NCCN as a group qualified to develop AUC and establish policy and decision-making for diagnostic imaging in patients with cancer. NCCN Imaging AUC are available free of charge to registered users of NCCN.org and can be accessed at NCCN.org/ImagingAUC.

“NCCN is proud of this acknowledgement from CMS, and we congratulate our fellow PLEs on their recognition,” said Robert W. Carlson, M.D., chief executive officer, NCCN. “At NCCN, we strive to improve the lives of people with cancer, and as a CMS-approved provider-led entity for development of diagnostic imaging AUC, we help to further assure that patients with cancer receive quality care while avoiding unnecessary diagnostic imaging.”

Adapted from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), NCCN Imaging AUC support clinical decision-making around the use of imaging in patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT), and ultrasound. NCCN is committed to assuring that the most up-to-date recommendations are available and reviews and updates the NCCN Imaging AUC™ on a continual basis to ensure that the recommendations take into account the most current evidence.

Today, NCCN Imaging AUC for the following NCCN Guidelines are available:
• Acute Lymphoblastic Leukemia, Version 1.2016
• Acute Myeloid Leukemia, Version 1.2016
• Bladder Cancer, Version 2.2016
• Breast Cancer, Version 2.2016
• Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2016
• Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2016
• Hodgkin Lymphoma, Version 3.2016
• Lung Cancer Screening, Version 2.2016
• Neuroendocrine Tumors, Version 2.2016
• Pancreatic Adenocarcinoma, Version 1.2016
• Prostate Cancer, Version 3.2016
• Prostate Cancer Early Detection, Version 2.2016
NCCN Imaging AUC for additional cancer types will be published in the coming months.

NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. Since June 2008, CMS has recognized the NCCN Drugs & Biologics Compendium (NCCN Compendium) as a mandated reference for establishment of coverage policy and coverage decisions regarding the use of drugs and biologics in cancer care.

For more information: NCCN.org/ImagingAUC

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Radiology Business | February 22, 2019
Imaging Technology News has been recognized with three award nominations from the Jesse H.
Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Welch Road Imaging Integrates RamSoft PowerServer RIS/PACS With openDoctor
News | PACS Accessories | February 20, 2019
Welch Road Imaging in California recently became the first RamSoft customer to integrate openDoctor with its...
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Sponsored Content | Webinar | Artificial Intelligence | February 14, 2019
This Nuance-sponsored ITN webinar will be held at 1 p.m. Eastern time, Tuesday, Feb. 26, 2019.